Allergic contact dermatitis
diseaseOn this page
Also known as allergic form of contact dermatitis
Summary
Allergic contact dermatitis (MONDO:0006525) is a disease and 26 clinical trials. Top therapeutic interventions include dupilumab, anakinra, and apremilast. A subtype of atopic eczema — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 26
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | allergic contact dermatitis |
| Mondo ID | MONDO:0006525 |
| EFO | EFO:1000668 |
| MeSH | D017449 |
| DOID | DOID:3042 |
| ICD-10-CM | L23 |
| ICD-11 | 2020673786 |
| NCIT | C26998 |
| SNOMED CT | 238575004 |
| UMLS | C0162820 |
| MedGen | 102474 |
| Is cancer (heuristic) | no |
Also known as: allergic contact dermatitis · allergic form of contact dermatitis
Disease family
This is a subtype of atopic eczema. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › skin disorder › dermatitis › atopic eczema › allergic contact dermatitis
Related subtypes (2): allergic cutaneous vasculitis, allergic urticaria
Subtypes (4): allergic contact dermatitis of eyelid, photoallergic dermatitis, toxicodendron dermatitis, 2-hydroxyethyl methacrylate sensitization
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 2 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Anakinra | Phase 3 (in late-stage trials) |
| Sodium Chloride | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Apremilast, Hyaluronidase (Human Recombinant).
Clinical trials & evidence
Clinical trials
Clinical trials: 26.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 15 |
| PHASE2 | 4 |
| PHASE4 | 2 |
| PHASE3 | 1 |
| PHASE2/PHASE3 | 1 |
| PHASE1/PHASE2 | 1 |
| PHASE1 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03935971 | PHASE4 | ACTIVE_NOT_RECRUITING | The Effects of Dupilumab on Allergic Contact Dermatitis |
| NCT01798589 | PHASE4 | COMPLETED | Bioequivalence of Ethylenediamine Dihydrochloride Study |
| NCT05535738 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation |
| NCT05498467 | PHASE3 | COMPLETED | The Role of Interleukin-1 Beta Targeted Therapy for Patients Suffering From Allergic Contact Dermatitis |
| NCT00132600 | PHASE2 | COMPLETED | Clinical Evaluation of Bacitracin |
| NCT00133341 | PHASE2 | COMPLETED | Clinical Evaluation of the 3 Allergens: Methyldibromoglutharonitrile, Parthenolide and Goldnatriumthiosulphate |
| NCT00867607 | PHASE1/PHASE2 | COMPLETED | Safety, Tolerability, and Efficacy of 21 Days Dermal Application of MRX-6 on Mild to Moderate Contact Dermatitis |
| NCT00931242 | PHASE2 | COMPLETED | Study of Apremilast in Atopic or Contact Dermatitis |
| NCT03680131 | PHASE2 | COMPLETED | Evaluation of EB01 Cream for the Treatment of Chronic Allergic Contact Dermatitis |
| NCT01244607 | PHASE1 | COMPLETED | NI-0801 in Allergic Contact Dermatitis |
| NCT03945760 | EARLY_PHASE1 | COMPLETED | Efficacy of Baricitinib In Treatment of Delayed-Type Hypersensitivity Versus Irritant Skin Reactions in Healthy Adult Male Subjects |
| NCT06351449 | Not specified | NOT_YET_RECRUITING | Characterization of Visual Characteristics in Allergic Contact Dermatitis Using the Skincam® Tool |
| NCT06529913 | Not specified | RECRUITING | Environmental Exposure to Heavy Metals, Nanoparticles, and Emergent Contaminants and Risk of Allergic Diseases |
| NCT06957444 | Not specified | ENROLLING_BY_INVITATION | Rate of Allergic Contact Dermatitis and Cosmetic Outcomes |
| NCT07573202 | Not specified | NOT_YET_RECRUITING | Evaluation of Hypersensitivity Reactions to Silk Fibroin Versus 2-octyl Cyanoacrylate Mesh in Shoulder Surgery |
| NCT00445029 | Not specified | UNKNOWN | Pathophysiological Study of Allergic Contact Dermatitis to Para-Phenylenediamine (PPD). Analysis of Cellular and Molecular Targets in Skin Inflammation |
| NCT01413477 | Not specified | UNKNOWN | Nickel Desensitization Using Topical Therapy |
| NCT01546298 | Not specified | COMPLETED | Immune Reactions in Contact Dermatitis Affected Skin |
| NCT01797562 | Not specified | COMPLETED | Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents |
| NCT02534441 | Not specified | COMPLETED | Epidemiology and Co-Reactivity of Novel Surfactant Allergens |
| NCT03902392 | Not specified | COMPLETED | Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis |
| NCT04365140 | Not specified | COMPLETED | MicroRNA-126 and Its Target VCAM-1Dermatitis to Nickel |
| NCT05339750 | Not specified | COMPLETED | Allergy Skin Patch Artificial Intelligence (AI) |
| NCT05858723 | Not specified | UNKNOWN | Repeated Open Application Test (ROAT) Study With Hydroperoxides of Linalool |
| NCT05991674 | Not specified | UNKNOWN | A Prospective Study to Investigate Contact Sensitization Using Classic and Machine Learning Techniques |
| NCT06191627 | Not specified | UNKNOWN | Patient Experience and Quality of Patch Testing on the Legs vs Back |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DUPILUMAB | 4 | 2 |
| ANAKINRA | 4 | 1 |
| APREMILAST | 4 | 1 |
| BACITRACIN | 4 | 1 |
| BETAMETHASONE VALERATE | 4 | 1 |
| CALCIPOTRIENE | 4 | 1 |
| CANAKINUMAB | 4 | 1 |
| GUSELKUMAB | 4 | 1 |
| SARILUMAB | 4 | 1 |
| USTEKINUMAB | 4 | 1 |
| NI-0801 | 2 | 1 |
| PARTHENOLIDE | 2 | 1 |
| SQUARIC ACID DIBUTYL ESTER | 2 | 1 |
| CHEMBL5220618 | 0 | 1 |
| CHEMBL3764363 | 0 | 1 |
| CHEMBL4096945 | 0 | 1 |
| CHEMBL4209556 | 0 | 1 |
| CHEMBL4303306 | 0 | 1 |
| CHEMBL3322516 | 0 | 1 |
| CHEMBL3780602 | 0 | 1 |
| CHEMBL4298697 | 0 | 1 |
| CHEMBL4580487 | 0 | 1 |
| CHEMBL465158 | 0 | 1 |
| CHEMBL477923 | 0 | 1 |
| CHEMBL4781244 | 0 | 1 |
| CHEMBL5176537 | 0 | 1 |
| CHEMBL475165 | 0 | 1 |
| CHEMBL4563773 | 0 | 1 |
| CHEMBL4796961 | 0 | 1 |